局部晚期宫颈癌无主动脉旁淋巴结累及者:疗前FDG-PET/CT代谢参数能否用于治疗调整
结果显示较高的宫颈SUVmax和TLG与放化疗反应差显著相关,多因素分析中宫颈SUVmax是总生存的主要预测因素。
要点
- 疗前宫颈SUVmax和TLG较高与放化疗反应差显著相关。
- 多因素分析中宫颈SUVmax是总生存的主要预测因素。
- 2年和5年总生存率分别为83.0%和71.2%。
核心结论
- 宫颈肿瘤SUVmax被证明是无主动脉旁淋巴结累及的局部晚期宫颈癌患者治疗反应和生存的无创预后生物标志物。
- SUVmax和其他PET/CT代谢参数需进一步前瞻性研究以帮助调整局部治疗。
研究设计与样本
- 所有患者接受至少45 Gy放疗和五个周期铂类化疗,排除高危组织学类型。
- 由两名妇科肿瘤核医学专家审阅所有PET/CT检查,提取肿瘤SUVmax、MTV和TLG。
- 放化疗反应通过45 Gy后盆腔MRI评估,病历回顾收集临床、病理和生存数据。
主要发现
- 2年和5年总生存率分别为83.0%[95%CI:72.5-89.8]和71.2%[57.5-81.2]。
- 2年和5年无复发生存率分别为72.5%[61.5-80.9]和64.4%[52.3-74.2]。
- 较高的宫颈SUVmax和TLG与放化疗反应差显著相关。
- 多因素分析中宫颈SUVmax是总生存的主要预测因素。
临床怎么用
- 疗前FDG-PET/CT的宫颈SUVmax和TLG可用于识别放化疗反应差和生存较差的高危患者。
- SUVmax作为无创预后标志物,有望辅助局部治疗方案的调整,但需前瞻性研究验证。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Aim of the study was to assess impact of pretherapeutic FDG-PET/CT metabolic parameters on response to chemoradiotherapy (CRT) and survival in locally advanced cervical cancer (LACC) patients without paraaortic lymph node involvement. METHODS: LACC patients treated with CRT without macrometastatic involvement after paraaortic surgical staging were included. All patients had received at least 45 Gy radiotherapy and five cycles of platinum-based chemotherapy. High-risk histologies were excluded. Two senior nuclear physician experts in gynaecologic oncology reviewed all PET/CT exams, and extracted tumor SUVmax, MTV, and TLG (standardized uptake value, metabolic tumor volume, and total lesion glycolysis respectively). Response to CRT was assessed with a pelvic MRI done after 45 Gy. Medical charts were reviewed for clinical, pathology, and survival data. RESULTS: Ninety-three patients were included in the study. The overall survival (OS) rates at 2 and 5 years were 83.0% [95%CI: 72.5-89.8] and 71.2% [57.5-81.2] respectively. The RFS rates at 2 and 5 years were 72.5% [61.5-80.9] and 64.4% [52.3-74.2] respectively. Higher cervical SUVmax and TLG were significantly associated with poor response to CRT. In multivariate analysis, cervical SUVmax was the main predictive factor for OS. CONCLUSION: Cervical tumor SUVmax was demonstrated to be a non-invasive prognostic biomarker for response to treatment and survival in LACC patients without paraaortic involvement. SUVmax and other PET/CT metabolic parameters require further prospective investigation to help tailoring of local treatment.
引用
- Voglimacci M, Gabiache E, Lusque A, et al. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring? Eur J Nucl Med Mol Imaging. 2019. PMID: 30729273. doi:10.1007/s00259-018-4219-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。